Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Craig Peppler

Interventional Pain Medicine Troy, MI Doctor of Osteopathy

NPI 1518908904 CMS profile 341530

2820 Crooks Rd, Suite 200, Troy, MI 48084

Open in the dashboard

General payments

$5,195

86 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Craig Peppler of Troy, MI is reported in the CMS Open Payments database as having received $5,195 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $54 3
2021 General $309 6
2020 General $4,035 31
2019 General $796 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Peppler
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Craig Peppler were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Craig Peppler Interventional Pain Medicine median Middle half National median
2019 $796 $684 $216–$2,079 $163
2020 $4,035 $382 $122–$1,109 $114
2021 $309 $552 $167–$1,554 $132
2022 $54 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Nevro Corp. $2,609 21 payments
  2. Horizon Therapeutics plc $1,500 1 payment
  3. Sentynl Therapeutics, Inc. $263 23 payments
  4. Scilex Pharmaceuticals Inc. $222 13 payments
  5. Flowonix Medical Incorporated $143 1 payment
  6. Pfizer Inc. $114 5 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $104 7 payments
  8. US WorldMeds, LLC $80 5 payments
  9. Zyla Life Sciences $47 3 payments
  10. Collegium Pharmaceutical, Inc. $43 3 payments
  11. Other $69 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,291 80 payments
  2. Honoraria $1,500 1 payment
  3. Travel and Lodging $1,404 5 payments
Products named General payments · program years 2019–2022
  1. Senza Spinal Cord Stimulation System $2,374 19 payments
  2. TEPEZZA $1,500 1 payment
  3. Levorphanol Tartrate $263 23 payments
  4. Omnia $235 2 payments
  5. Prometra II $143 1 payment
  6. ZTLido $116 7 payments
  7. Lucemyra/Lofexidine $80 5 payments
  8. RELISTOR $78 5 payments
  9. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $68 4 payments
  10. LYRICA $62 3 payments
  11. Other $310 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record